MA38284B1 - Inhibiteurs de la phospholipase associée aux lipoprotéines a2 (lp-pla2) à base de 2,3-dihydro-imidazol[1,2-c]pyrimidin-5(1 h)-one - Google Patents

Inhibiteurs de la phospholipase associée aux lipoprotéines a2 (lp-pla2) à base de 2,3-dihydro-imidazol[1,2-c]pyrimidin-5(1 h)-one

Info

Publication number
MA38284B1
MA38284B1 MA38284A MA38284A MA38284B1 MA 38284 B1 MA38284 B1 MA 38284B1 MA 38284 A MA38284 A MA 38284A MA 38284 A MA38284 A MA 38284A MA 38284 B1 MA38284 B1 MA 38284B1
Authority
MA
Morocco
Prior art keywords
dihydroimidazol
pla2
lipoprotein
pyrimidin
inhibitors
Prior art date
Application number
MA38284A
Other languages
English (en)
Other versions
MA38284A1 (fr
Inventor
Yingxia Sang
Zehong Wan
Qing Zhang
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50002724&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA38284(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of MA38284A1 publication Critical patent/MA38284A1/fr
Publication of MA38284B1 publication Critical patent/MA38284B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne de nouveaux composés qui inhibent l'activité de la lp-pla2, des procédés pour leur préparation, des compositions les contenant et leur utilisation pour le traitement de maladies associées à l'activité de la lp-pla2, par exemple l'athérosclérose et la maladie d'alzheimer.
MA38284A 2013-01-25 2014-01-23 Inhibiteurs de la phospholipase associée aux lipoprotéines a2 (lp-pla2) à base de 2,3-dihydro-imidazol[1,2-c]pyrimidin-5(1 h)-one MA38284B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2013070976 2013-01-25
CN2013001556 2013-12-12
PCT/EP2014/051286 WO2014114694A1 (fr) 2013-01-25 2014-01-23 Inhibiteurs de la phospholipase associée aux lipoprotéines a2 (lp-pla2) à base de 2,3-dihydro-imidazol[1,2-c]pyrimidin-5(1 h)-one

Publications (2)

Publication Number Publication Date
MA38284A1 MA38284A1 (fr) 2017-12-29
MA38284B1 true MA38284B1 (fr) 2018-05-31

Family

ID=50002724

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38284A MA38284B1 (fr) 2013-01-25 2014-01-23 Inhibiteurs de la phospholipase associée aux lipoprotéines a2 (lp-pla2) à base de 2,3-dihydro-imidazol[1,2-c]pyrimidin-5(1 h)-one

Country Status (23)

Country Link
US (1) US9708330B2 (fr)
EP (1) EP2948452B1 (fr)
JP (1) JP6306053B2 (fr)
KR (1) KR20150108897A (fr)
CN (1) CN105008368B (fr)
AU (1) AU2014209949B2 (fr)
BR (1) BR112015017759B1 (fr)
CA (1) CA2899091A1 (fr)
CL (1) CL2015002060A1 (fr)
CR (1) CR20150390A (fr)
EA (1) EA025885B1 (fr)
ES (1) ES2642762T3 (fr)
HK (1) HK1216425A1 (fr)
IL (1) IL240046A0 (fr)
MA (1) MA38284B1 (fr)
MX (1) MX2015009633A (fr)
PE (1) PE20151251A1 (fr)
PH (1) PH12015501586A1 (fr)
SG (1) SG11201505520WA (fr)
TW (1) TW201443054A (fr)
UY (1) UY35276A (fr)
WO (1) WO2014114694A1 (fr)
ZA (1) ZA201505025B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105008368B (zh) 2013-01-25 2017-02-01 葛兰素史密斯克莱知识产权发展有限公司 基于2,3‑二氢咪唑并[1,2‑c]嘧啶‑5(1H)‑酮的脂蛋白相关磷脂酶A2(Lp‑PLA2)抑制剂
WO2016012916A1 (fr) * 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited Dérivés 1,2,3,5-tétrahydro-imidazo [1,2-c]pyrimidine utiles pour le traitement de maladies et de troubles médiés par la lp-pla2
WO2016011931A1 (fr) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited Composés
WO2016012917A1 (fr) * 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited Dérivés 1,2,3,5-tétrahydro-imidazo [1,2-c]pyrimidine utiles pour le traitement de maladies et de troubles médiés par la lp-pla2
CN104892459A (zh) * 2015-06-16 2015-09-09 苏州明锐医药科技有限公司 利奥西呱中间体及其制备方法
CN112574221B (zh) * 2019-09-30 2022-03-04 上海纽思克生物科技有限公司 四环嘧啶酮类化合物、其制备方法、其组合物和用途
CA3156783A1 (fr) * 2019-11-09 2021-05-14 Yun Jin Derive de dihydroimidazopyrimidone tricyclique, son procede de preparation, composition pharmaceutique et son utilisation
CN111533699B (zh) * 2020-05-27 2023-12-01 龙曦宁（上海）医药科技有限公司 一种2-（三氟甲基）嘧啶-5-醇的合成方法
CN113861220B (zh) * 2020-06-30 2023-06-16 上海纽思克生物科技有限公司 三环嘧啶酮类化合物、其制备方法、其组合物和用途
CN113912622B (zh) * 2020-07-10 2023-12-01 上海纽思克生物科技有限公司 三环嘧啶酮类化合物、其制备方法、其组合物和用途
CN115304620A (zh) 2021-05-07 2022-11-08 上海赛默罗生物科技有限公司 嘧啶酮衍生物、其制备方法、药物组合物和用途
CN114057740B (zh) * 2021-12-15 2024-04-02 上海赛默罗生物科技有限公司 螺环嘧啶酮衍生物、其制备方法、药物组合物和用途
CN116120329A (zh) * 2022-08-04 2023-05-16 福贝生物医药科技(北京)有限公司 作为Lp-PLA2抑制剂的新型化合物及其用途

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993018035A1 (fr) 1992-03-04 1993-09-16 Abbott Laboratories Antagonistes des recepteurs de l'angiotensine ii
GB9421816D0 (en) 1994-10-29 1994-12-14 Smithkline Beecham Plc Novel compounds
CA2208530A1 (fr) 1994-12-22 1996-06-27 Smithkline Beecham P.L.C. Azetidin-2-ones substituees, destinees au traitement de l'atherosclerose
CH690264A5 (fr) 1995-06-30 2000-06-30 Symphar Sa Dérivés aminophosphonates substitués, leur procédé de préparation et leur utilisation pour la préparation de compositions pharmaceutiques.
SK178497A3 (en) 1995-07-01 1998-07-08 Smithkline Beecham Plc Azetidinone derivatives, method for producing the same, pharmaceutical composition containing same and their use
WO1997012963A2 (fr) 1995-09-29 1997-04-10 Smithkline Beecham Plc Paf-acetylhydrolase paf et son utilisation en therapie
WO1997021676A1 (fr) 1995-12-08 1997-06-19 Smithkline Beecham Plc Composes azetidinone destines au traitement de l'atherosclerose
EP0869943A1 (fr) 1995-12-08 1998-10-14 Smithkline Beecham Plc Derives de beta-lactame monocycliques utilises dans le traitement de l'atherosclerose
EP0915843A1 (fr) 1996-04-26 1999-05-19 Smithkline Beecham Plc Derives azetidinones destines au traitement de l'atherosclerose
GB9608649D0 (en) 1996-04-26 1996-07-03 Smithkline Beecham Plc Novel compounds
GB9626536D0 (en) 1996-12-20 1997-02-05 Symphar Sa Novel compounds
GB9626616D0 (en) 1996-12-20 1997-02-05 Symphar Sa Novel compounds
GB9626615D0 (en) 1996-12-20 1997-02-05 Symphar Sa Novel compounds
US6417192B1 (en) 1997-11-06 2002-07-09 Smithkline Beecham P.L.C. Pyrimidinone compounds and pharmaceutical compositions containing them
DE69911980T2 (de) 1998-08-21 2004-09-09 Smithkline Beecham P.L.C., Brentford Pyrimidinonderivate zur behandlung von atheroscleros
GB9910079D0 (en) 1999-05-01 1999-06-30 Smithkline Beecham Plc Novel compounds
US6953803B1 (en) 1999-05-01 2005-10-11 Smithkline Beecham P.L.C. Pyrimidine compounds
GB9910378D0 (en) 1999-05-05 1999-06-30 Smithkline Beecham Plc Novel compounds
JP3757703B2 (ja) 1999-09-22 2006-03-22 凸版印刷株式会社 再封可能な開口維持部材付パウチ
CZ304450B6 (cs) 2000-02-16 2014-05-14 Smithkline Beecham P. L. C. Pyrimidinový derivát
GB0024807D0 (en) 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
GB0024808D0 (en) 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
GB0119795D0 (en) 2001-08-14 2001-10-03 Smithkline Beecham Plc Novel process
GB0119793D0 (en) 2001-08-14 2001-10-03 Smithkline Beecham Plc Novel compounds
GB0127141D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Plc Novel compounds
GB0127139D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0127143D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0127140D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0208280D0 (en) 2002-04-10 2002-05-22 Glaxo Group Ltd Novel compounds
GB0208279D0 (en) 2002-04-10 2002-05-22 Glaxo Group Ltd Novel compounds
EP1644353A1 (fr) 2003-07-02 2006-04-12 Bayer HealthCare AG 1,2,4-triazino-5(2h)-ones a substitution amide destinees au traitement de maladies inflammatoires chroniques
DE102004061009A1 (de) 2004-12-18 2006-06-22 Bayer Healthcare Ag Substituierte 1,2,4-Triazin-5(2H)-one
DE102004061008A1 (de) 2004-12-18 2006-06-22 Bayer Healthcare Ag 3-Arylalkyl- und 3-Heteroarylalkyl-substituierte 1,2,4-Triazin-5(2H)-one
EP2083625A4 (fr) 2006-10-13 2011-10-19 Glaxo Group Ltd Composés hétoroaromatiques bicycliques
US20080090851A1 (en) 2006-10-13 2008-04-17 Colin Andrew Leach Bicyclic Heteroaromatic Compounds
US20080090852A1 (en) 2006-10-13 2008-04-17 Colin Andrew Leach Bicyclic Heteroaromatic Compounds
US7705005B2 (en) 2006-10-13 2010-04-27 Glaxo Group Limited Bicyclic heteroaromatic compounds
WO2008104077A1 (fr) 2007-02-28 2008-09-04 Methylgene Inc. Inhibiteurs à petite molécule de protéines arginine méthyltransférases (prmt)
EA018101B1 (ru) 2007-05-11 2013-05-30 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Способы лечения кожных язв
US8962633B2 (en) 2007-05-11 2015-02-24 Thomas Jefferson University Methods of treatment and prevention of metabolic bone diseases and disorders
US20080279846A1 (en) 2007-05-11 2008-11-13 Thomas Jefferson University Methods of treatment and prevention of neurodegenerative diseases and disorders
JP2011088847A (ja) * 2009-10-21 2011-05-06 Takeda Chem Ind Ltd 三環性化合物およびその用途
JP2013537203A (ja) * 2010-09-20 2013-09-30 グラクソ グループ リミテッド 三環式化合物、製造方法、およびそれらの使用
WO2012075917A1 (fr) * 2010-12-06 2012-06-14 Glaxo Group Limited Composés
EP2651403B1 (fr) 2010-12-17 2020-12-02 Glaxo Group Limited Procédés de traitement et de prévention de maladies oculaires
CN103827116B (zh) 2011-07-27 2016-08-31 葛兰素集团有限公司 用作LP-PLA2抑制剂的2,3-二氢咪唑并[1,2-c]嘧啶-5(1H)-酮化合物
KR20140059203A (ko) * 2011-07-27 2014-05-15 글락소 그룹 리미티드 2,3-디히드로이미다조[1,2-c]피리미딘-5(1h)-온 화합물의 lp-pla2 억제제로서의 용도
CN105008368B (zh) 2013-01-25 2017-02-01 葛兰素史密斯克莱知识产权发展有限公司 基于2,3‑二氢咪唑并[1,2‑c]嘧啶‑5(1H)‑酮的脂蛋白相关磷脂酶A2(Lp‑PLA2)抑制剂

Also Published As

Publication number Publication date
ES2642762T3 (es) 2017-11-20
WO2014114694A1 (fr) 2014-07-31
BR112015017759A2 (pt) 2017-07-11
IL240046A0 (en) 2015-08-31
UY35276A (es) 2014-08-29
JP6306053B2 (ja) 2018-04-04
JP2016505058A (ja) 2016-02-18
EP2948452A1 (fr) 2015-12-02
CR20150390A (es) 2015-10-19
EA201591379A1 (ru) 2016-01-29
TW201443054A (zh) 2014-11-16
EA025885B1 (ru) 2017-02-28
SG11201505520WA (en) 2015-08-28
AU2014209949A1 (en) 2015-07-30
MX2015009633A (es) 2015-11-30
HK1216425A1 (zh) 2016-11-11
BR112015017759B1 (pt) 2022-05-24
KR20150108897A (ko) 2015-09-30
US20150361082A1 (en) 2015-12-17
CN105008368B (zh) 2017-02-01
PE20151251A1 (es) 2015-09-10
CN105008368A (zh) 2015-10-28
CL2015002060A1 (es) 2015-11-27
US9708330B2 (en) 2017-07-18
ZA201505025B (en) 2017-08-30
CA2899091A1 (fr) 2014-07-31
PH12015501586A1 (en) 2015-10-05
EP2948452B1 (fr) 2017-08-09
AU2014209949B2 (en) 2016-09-08
MA38284A1 (fr) 2017-12-29

Similar Documents

Publication Publication Date Title
MA38284B1 (fr) Inhibiteurs de la phospholipase associée aux lipoprotéines a2 (lp-pla2) à base de 2,3-dihydro-imidazol[1,2-c]pyrimidin-5(1 h)-one
MA39219A1 (fr) Nouveaux composés inhibiteurs de la kinase lrrk2 utilisés pour le traitement du parkinson, de l’alzheimer et de la sclérose latérale amyotrophique
MA49809A1 (fr) Composés utilisés comme inhibiteurs de kinase
MA39211A1 (fr) Composés tricycliques comme agents anti-cancers
MA44948A1 (fr) Inhibiteurs de bace 1
EA201792047A1 (ru) Новые соединения
MA41134A (fr) Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales
EA202091709A1 (ru) Ингибиторы днк-пк
MA38483A1 (fr) Inhibiteurs de l'ido
TN2009000551A1 (fr) Nouveaux composes chimiques
MA39193A1 (fr) Modulateurs du gpr6 à base de tétrahydropyridopyrazines
MA35748B1 (fr) Fluorométhyl-5,6-dihydro-4h-[1,3]oxazines
MA38190A2 (fr) Inhibiteurs d'autotaxine
MA38327A2 (fr) Dihydropyrimidinones bicycliques substituées et leur utilisation à titre d'inhibiteurs de l'activité élastase neutrophile
MA39145B1 (fr) Dérivés de pipérazine ayant une activité multimode contre la douleur
TN2016000188A1 (fr) Derives de purines 2,6-substitues et leur utilisation dans le traitement de troubles proliferatifs.
EA202091708A1 (ru) Ингибиторы днк-пк
MA37691B1 (fr) 5-amino[1,4]thiazines comme inhibiteurs de bace1
MA41494B1 (fr) Composés benzoxaborole substitués en position 4 et utilisations associées
MA38925B1 (fr) Dérivés de phénylalanine substitués
MA43250B1 (fr) Composés d'oxadiazaspiro pour le traitement de l'abus et la dépendance aux drogues
FR2968662B1 (fr) Nouveaux derives d'oxazaphosphorines pre-activees, utilisation et methode de preparation
MA39533A1 (fr) Composés, composition pharmaceutique et leur utilisation dans le traitement de maladies neurodégénératives
MA33938B1 (fr) 5-alcynyl-pyrimidines
MA44025A1 (fr) Inhibiteurs de pde9 pour le traitement de maladies périphériques